BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 11747320)

  • 1. Activation and activities of the p53 tumour suppressor protein.
    Bálint E E; Vousden KH
    Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts.
    Gentiletti F; Mancini F; D'Angelo M; Sacchi A; Pontecorvi A; Jochemsen AG; Moretti F
    Oncogene; 2002 Jan; 21(6):867-77. PubMed ID: 11840332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63.
    Little NA; Jochemsen AG
    Oncogene; 2001 Jul; 20(33):4576-80. PubMed ID: 11494153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
    Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensing cellular stress: another new function for the nucleolus?
    Olson MO
    Sci STKE; 2004 Mar; 2004(224):pe10. PubMed ID: 15026578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation.
    Okada Y; Osada M; Kurata S; Sato S; Aisaki K; Kageyama Y; Kihara K; Ikawa Y; Katoh I
    Exp Cell Res; 2002 Jun; 276(2):194-200. PubMed ID: 12027449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells.
    Pan Y; Haines DS
    Cancer Res; 1999 May; 59(9):2064-7. PubMed ID: 10232588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.
    Ljungman M
    Neoplasia; 2000; 2(3):208-25. PubMed ID: 10935507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of p53 stability by Mdm2.
    Kubbutat MH; Jones SN; Vousden KH
    Nature; 1997 May; 387(6630):299-303. PubMed ID: 9153396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53.
    Jackson MW; Agarwal MK; Agarwal ML; Agarwal A; Stanhope-Baker P; Williams BR; Stark GR
    Oncogene; 2004 May; 23(25):4477-87. PubMed ID: 15064747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.
    Chang YC; Lee YS; Tejima T; Tanaka K; Omura S; Heintz NH; Mitsui Y; Magae J
    Cell Growth Differ; 1998 Jan; 9(1):79-84. PubMed ID: 9438391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
    Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
    Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
    Chène P
    Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.
    Hastak K; Gupta S; Ahmad N; Agarwal MK; Agarwal ML; Mukhtar H
    Oncogene; 2003 Jul; 22(31):4851-9. PubMed ID: 12894226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes.
    Kashuba E; Mattsson K; Klein G; Szekely L
    Mol Cancer; 2003 Mar; 2():18. PubMed ID: 12685933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation.
    Qiao D; Gaitonde SV; Qi W; Martinez JD
    Carcinogenesis; 2001 Jun; 22(6):957-64. PubMed ID: 11375905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.